![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Background: Endometrial cancer (EC) occurs most commonly after menopause. A proportion of patients present with advanced age and comorbidities, and become ineligible for surgery. The optimal treatment strategy of these patients remains a clinical challenge. Aromatase inhibitor (AI) combined with Gonadotropin-releasing hormone agonist (GnRH-a) possesses profound effect in suppressing the estrogen level, has become a valid treatment in the breast cancer. However, the combined use of an AI and a GnRH-a in EC has rarely been studied.
Case presentation: Herein, we report the combination of an AI and a GnRH-a in the treatment of three patients with advanced age or comorbidities who were ineligible for surgery. The disease remained stable for two years in patients who received the combination treatment as an initial approach without any adverse effects. Moreover, an AI combined with a GnRH-a also effective as salvage treatment of recurrent patients. Further, we provide a brief review of the literature.
Conclusion: The combination of an AI and a GnRH-a presents satisfactory therapeutic effect and provides an optimal option for inoperable EC patients.
Abbreviations
| EC | = | Endometrial cancer |
| PFS | = | progression free survival |
| GI | = | gastrointestinal |
| MRI | = | Magnetic resonance imaging |
| AI | = | Aromatase inhibitor |
| GnRH-a | = | Gonadotropin-releasing hormone agonist |
| LNG-IUD | = | levonorgestrel-releasing intrauterine device |
| BMI | = | body mass index |
| LHRH | = | luteinising hormone-releasing hormone |
| PR | = | progesterone receptor |
| OS | = | overall survival |
Declarations
Ethics approval and consent to participate
Ethics approval for the study was gained from the ethical review committee of Tianjin Medical University General Hospital. Patients and their relatives provide their consents to the treatment.
Consent for publication
Informed consents were obtained from patients and their relatives.
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
Author contributions
Manuscript outline and content: MD WT. Literature search: SJ YY CG. Figures: MD YS JG. Writing and review of the manuscript writing: MD SJ. Final manuscript approval: MD SJ WT YY CG JG YS YW FX.
Acknowledgments
This study was supported by the Natural Science Foundation of China under Grant No. 81572568 to Y. Wang and No. 81602293 to W. Tian.